122,237 Shares in CryoPort, Inc. $CYRX Purchased by Nuveen LLC

Nuveen LLC purchased a new stake in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 122,237 shares of the company's stock, valued at approximately $743,000. Nuveen LLC owned about 0.24% of CryoPort as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of CYRX. Wells Fargo & Company MN lifted its position in shares of CryoPort by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 28,767 shares of the company's stock valued at $224,000 after buying an additional 6,533 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of CryoPort in the 4th quarter valued at approximately $194,000. Barclays PLC raised its position in shares of CryoPort by 8.9% in the 4th quarter. Barclays PLC now owns 88,654 shares of the company's stock valued at $690,000 after purchasing an additional 7,237 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of CryoPort by 8.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 850,216 shares of the company's stock valued at $6,615,000 after purchasing an additional 63,301 shares during the last quarter. Finally, Stifel Financial Corp raised its position in shares of CryoPort by 26.4% in the 4th quarter. Stifel Financial Corp now owns 176,607 shares of the company's stock valued at $1,374,000 after purchasing an additional 36,862 shares during the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

CryoPort Trading Up 16.9%

Shares of NASDAQ CYRX traded up $1.50 during trading on Friday, hitting $10.35. 1,057,323 shares of the company were exchanged, compared to its average volume of 564,492. CryoPort, Inc. has a 12-month low of $4.58 and a 12-month high of $10.39. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24. The company has a fifty day moving average price of $8.03 and a 200-day moving average price of $6.79. The firm has a market capitalization of $518.22 million, a PE ratio of 7.78 and a beta of 1.62.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%.The company had revenue of $45.45 million for the quarter, compared to analysts' expectations of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that CryoPort, Inc. will post -0.99 EPS for the current year.

Analysts Set New Price Targets

CYRX has been the subject of several research analyst reports. Leerink Partnrs raised shares of CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 6th. KeyCorp upgraded shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price target on the stock in a report on Wednesday, August 6th. Stephens began coverage on shares of CryoPort in a report on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 price target on the stock. BTIG Research dropped their price objective on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, July 7th. Finally, Leerink Partners raised shares of CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price target on the stock in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $12.00.

Insider Buying and Selling

In other news, CFO Robert Stefanovich sold 9,300 shares of CryoPort stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total transaction of $80,631.00. Following the transaction, the chief financial officer owned 207,213 shares in the company, valued at $1,796,536.71. The trade was a 4.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jerrell Shelton sold 151,304 shares of the firm's stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $6.81, for a total value of $1,030,380.24. Following the sale, the chief executive officer directly owned 912,419 shares of the company's stock, valued at $6,213,573.39. The trade was a 14.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 492,247 shares of company stock worth $3,384,579 in the last quarter. 10.10% of the stock is currently owned by insiders.

CryoPort Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.